Literature DB >> 17267927

Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial.

Brian Hallahan1, Joseph R Hibbeln, John M Davis, Malcolm R Garland.   

Abstract

BACKGROUND: Trials have demonstrated benefits of long-chain omega-3 essential fatty acid (n-3 EFA) supplementation in a variety of psychiatric disorders. AIMS: To assess the efficacy of n-3 EFAs in improving psychological well-being in patients with recurrent self-harm.
METHOD: Patients (n=49) presenting after an act of repeated self-harm were randomised to receive 1.2 g eicosapentaenoic acid plus 0.9 g decosahexaenoic acid (n=22) or placebo (n=27) for 12 weeks in addition to standard psychiatric care. Six psychological domains were measured at baseline and end point.
RESULTS: At 12 weeks, the n-3 EFA group had significantly greater improvements in scores for depression, suicidality and daily stresses. Scores for impulsivity, aggression and hostility did not differ.
CONCLUSIONS: Supplementation achieved substantial reductions in surrogate markers of suicidal behaviour and improvements in well-being. Larger studies are warranted to determine if insufficient dietary intake of n-3 EFAs is a reversible risk factor for self-harm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267927     DOI: 10.1192/bjp.bp.106.022707

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  42 in total

1.  Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  J Psychosom Res       Date:  2013-07-26       Impact factor: 3.006

Review 2.  Pharmacotherapy for borderline personality disorder--current evidence and recent trends.

Authors:  Jutta M Stoffers; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

Review 3.  The Role of Nutrients in Protecting Mitochondrial Function and Neurotransmitter Signaling: Implications for the Treatment of Depression, PTSD, and Suicidal Behaviors.

Authors:  Jing Du; Ming Zhu; Hongkun Bao; Bai Li; Yilong Dong; Chunjie Xiao; Grace Y Zhang; Ioline Henter; Matthew Rudorfer; Benedetto Vitiello
Journal:  Crit Rev Food Sci Nutr       Date:  2016-11-17       Impact factor: 11.176

4.  Corporate externalities: a challenge to the further success of prevention science.

Authors:  Anthony Biglan
Journal:  Prev Sci       Date:  2011-03

5.  A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.

Authors:  David Mischoulon; George I Papakostas; Christina M Dording; Amy H Farabaugh; Shamsah B Sonawalla; A Monica Agoston; Juliana Smith; Erin C Beaumont; Liat E Dahan; Jonathan E Alpert; Andrew A Nierenberg; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2009-08-25       Impact factor: 4.384

6.  Aggressive dogs are characterized by low omega-3 polyunsaturated fatty acid status.

Authors:  Simona Re; Marco Zanoletti; Enzo Emanuele
Journal:  Vet Res Commun       Date:  2007-09-19       Impact factor: 2.459

7.  Plasma linoleic acid partially mediates the association of bipolar disorder on self-reported mental health scales.

Authors:  Simon J Evans; Shervin Assari; Gloria J Harrington; Ya-Wen Chang; Charles F Burant; Melvin G McInnis
Journal:  J Psychiatr Res       Date:  2015-06-14       Impact factor: 4.791

8.  Role of Long-Chain Omega-3 Fatty Acids in Psychiatric Practice.

Authors:  Robert K McNamara; Jeffrey R Strawn
Journal:  PharmaNutrition       Date:  2013-04

Review 9.  Complementary and alternative medicine therapies to promote healthy moods.

Authors:  Kathi J Kemper; Scott Shannon
Journal:  Pediatr Clin North Am       Date:  2007-12       Impact factor: 3.278

10.  5-Lipoxygenase in the Prefrontal Cortex of Suicide Victims.

Authors:  Tolga Uz; Yogesh Dwivedi; Ghanshyam N Pandey; Rosalinda C Roberts; Robert R Conley; Radmila Manev; Hari Manev
Journal:  Open Neuropsychopharmacol J       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.